← All trials
NCT07082114
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2025
- Primary completion
- Feb 16, 2027
- Completion date
- May 17, 2027
- First posted
- Jul 24, 2025
- Last posted
- Jul 24, 2025
- Enrollment
- 800
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou ZhongmeiLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.